title: In vitro effect of calcium dobesilate on oxidative/inflammatory stress in human varicose veins.
abstract: OBJECTIVE
  To determine whether calcium dobesilate can act in chronic venous insufficiency by similar antioxidant, anti-inflammatory mechanisms as in diabetic retinopathy.
  
  
  METHODS
  Calcium dobesilate was tested in vitro for its protective action against oxidative/inflammatory stress in human varicose veins. Varicose greater saphenous veins were obtained from 14 patients (11 men, 3 women) aged 53-65 years. Oxidative stress was induced exogenously in the vein segments, with the phenazine methosulphate (PMS)/NADH couple. Total antioxidant status (TAS) and malondialdehyde (MDA) contents were used as markers of oxidative stress.
  
  
  RESULTS
  Calcium dobesilate significantly prevented oxidative disturbances in the micromolar range. PMS/NADH-dependent TAS decrease was fully prevented with IC(50) = 11.4 ± 2.3 µmol/L (n = 6 veins), whereas MDA increase was fully prevented with IC(50) = (102 ± -3) µmol/L (n = 6 veins). Calcium dobesilate acted quali- and quantitatively like rutin, the reference compound. Comparison with pharmacokinetic data suggests that calcium dobesilate can act at therapeutic concentrations.
  
  
  CONCLUSIONS
  Calcium dobesilate protected human varicose veins against oxidative stress in vitro at levels that correspond to therapeutic concentrations. Further studies are required to investigate whether a similar action is found in varicose veins from patients orally treated with calcium dobesilate.
authors.affiliation: Physiology & Pharmacology, School of Medicine of Zaragoza, Spain.
authors.forename: O
authors.initials: O
authors.lastname: Alda
authors.forename: M S
authors.initials: MS
authors.lastname: Valero
authors.forename: D
authors.initials: D
authors.lastname: Pereboom
authors.forename: P
authors.initials: P
authors.lastname: Serrano
authors.forename: J M
authors.initials: JM
authors.lastname: Azcona
authors.forename: R P
authors.initials: RP
authors.lastname: Garay
mesh_terms: D000368:Aged; D000975:Antioxidants / Q000378:metabolism*; D002123:Calcium Dobesilate / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006490:Hemostatics / Q000494:pharmacology*; D006801:Humans; D007249:Inflammation / Q000139:chemically induced / Q000188:drug therapy / Q000473:pathology / Q000503:physiopathology; D008297:Male; D008315:Malondialdehyde / Q000378:metabolism*; D008773:Methylphenazonium Methosulfate / Q000633:toxicity; D008875:Middle Aged; D009924:Organ Culture Techniques; D018384:Oxidative Stress / Q000187:drug effects*; D012501:Saphenous Vein / Q000378:metabolism* / Q000473:pathology / Q000503:physiopathology; D014648:Varicose Veins / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology / Q000503:physiopathology
chemical_list: D000975:Antioxidants; D006490:Hemostatics; D008773:Methylphenazonium Methosulfate; D008315:Malondialdehyde; D002123:Calcium Dobesilate